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1682-606X/Copyright ª 2015, TaiwanSummary Background/Introduction: Dialysis modalities may influence parathyroid hormone
(PTH) levels and renal osteodystrophy patterns. To date, no study has compared the effects of
dialysis modality on surgical patients with renal hyperparathyroidism.
Purpose/Aim: This study evaluated the influence of different dialysis modalities on perioper-
ative features among patients undergoing parathyroidectomy.
Methods: Overall, 386 patients who underwent initial parathyroidectomy for renal hyperpara-
thyroidism were recruited. Biochemical data and relevant symptoms were compared between
hemodialysis and peritoneal dialysis patients.
Results: Compared with the hemodialysis patients, the 40 (10%) peritoneal dialysis patients
were younger (p Z 0.002) and had a shorter duration of dialysis (p < 0.001). The peritoneal
dialysis patients had lower hemoglobin (pZ 0.006), albumin (pZ 0.040), and intact PTH levels
(pZ 0.039) prior to surgery but had higher serum aluminum levels (pZ 0.039). During follow-
up, the peritoneal dialysis patients tended to have higher calciumephosphorus product levels
and more severe residual symptoms of bone pain (p Z 0.080), mood swings (p Z 0.053), and
pruritus (p Z 0.094).
Conclusion: Patients on different dialysis modalities had similar decreases in intact PTH and
alkaline phosphatase levels after surgery. However, the peritoneal dialysis patients had higher
postoperative calciumephosphorus product levels and more severe residual symptoms.
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152 K.-C. Ho et al.1. IntroductionMineral dysfunction and hyperparathyroidism are common
complications of end-stage renal disease (ESRD). The
prevalence of renal hyperparathyroidism among dialysis
populations ranges from 12% to 54%.1 Elevated levels of
parathyroid hormone (PTH) are associated with several in-
flammatory markers.2 For patients with severe uncontrol-
lable hyperparathyroidism, parathyroidectomy may
improve overall survival,3 bone mineral density (BMD),4 and
quality of life as well as alleviate symptoms5 and fracture
nonunion.6 In the United States, the rate of para-
thyroidectomy declined between 1988 and 1998 but
increased thereafter, despite advances in medical
treatment.7
For patients requiring renal replacement therapy, no
clear survival benefit exists for hemodialysis or peritoneal
dialysis.8 Nonetheless, dialysis modalities significantly
influence hemoglobin, ferritin, albumin, cholesterol, and
PTH levels.9 Some studies have shown that the prevalence
of adynamic bone disease is consistently higher in perito-
neal dialysis patients than in hemodialysis patients.10 To
our knowledge, no study has compared the effects of
dialysis modality on surgical patients with renal hyper-
parathyroidism. This study evaluated the influence of
different dialysis modalities on perioperative features
among patients undergoing parathyroidectomy for renal
hyperparathyroidism.
2. Methods
From January 2004 to December 2014, 389 consecutive
ESRD patients underwent initial parathyroidectomy for
renal hyperparathyroidism at a tertiary care center. Three
patients younger than 20 years were excluded. Overall, 386
patients who had biochemically confirmed renal hyper-
parathyroidism comprised the study population. The indi-
cation for parathyroidectomy was severe
hyperparathyroidism associated with hypercalcemia and/or
hyperphosphatemia that was refractory to medical
therapy.11
Serum calcium, phosphate, total alkaline phosphatase,
albumin, and intact PTH levels (1e84) were regularly
monitored preoperatively and during follow-up.12 Most
referring dialysis centers examined electrolytes on a
monthly basis and alkaline phosphatase and PTH levels at 3-
month intervals. When the serum albumin level was <4.0 g/
dL, serum calcium levels were corrected using the following
formula:
corrected calcium (mg/dL) Z measured total calcium
(mg/dL) þ 0.8  [4.0  serum albumin (g/dL)]. (1)
BMD at the lumbar spine and hip was measured using
dual-energy X-ray absorptiometry. After August 2008, the
serum aluminum level was determined preoperatively and/
or within 1 week after surgery.13
All operations were performed or supervised by board-
certified endocrine surgeons. Bilateral cervical exploration
was followed by subtotal parathyroidectomy or total
parathyroidectomy with or without autotransplantation14;the decision was at the discretion of the operating surgeon.
After parathyroidectomy, persistent disease was defined as
any measurement of an intact PTH level >300 pg/mL in the
postoperative 6 months. Recurrence was defined as any
measurement of an intact PTH level >300 pg/mL beyond 6
months after surgery.11
After August 2008, the Parathyroidectomy Assessment of
Symptoms (PAS) questionnaire was used to assess relevant
symptoms preoperatively and 6e12 months after the sur-
gery. The PAS scoring system addresses 13 parameters: pain
in the bones, feeling tired easily, mood swings, feeling
“blue” or depressed, pain in the abdomen, feeling weak,
feeling irritable, pain in the joints, being forgetful, diffi-
culty getting out of a chair or car, headaches, itchy skin,
and being thirsty.15 Each item was scored on a 100-point
visual analog scale, and the PAS score was calculated as
the sum of all 13 answers (range, 0e1300). The reliability
and validity of the Taiwan Chinese-translated version were
established in our previous study.5
Data were analyzed using STATA 12.0 (Stata Corp., Col-
lege Station, TX, USA) and are reported as the
mean  standard deviation. Natural log or square root
transformations were performed when necessary to
normalize skewed distributions. Categorical data were
compared using Fisher’s exact test or the Chi-square test,
as appropriate. A paired or unpaired Student t test was
used to evaluate differences between groups. All statistical
tests were two-sided, and statistical significance was
determined as p < 0.05.3. Results
Of the 386 patients, 346 (90%) were on regular hemodi-
alysis and 40 (10%) were on regular peritoneal dialysis.
The peritoneal dialysis patients were significantly younger
and had a shorter duration of dialysis compared with the
hemodialysis patients (Table 1). The mean duration of
dialysis prior to surgery was 9.9  4.9 years and 6.3  3.9
years for the hemodialysis patients and peritoneal dialysis
patients, respectively. The peritoneal dialysis patients
had lower hemoglobin, albumin, and intact PTH levels
compared with the hemodialysis patients. Prior to
parathyroidectomy, no differences existed in serum cal-
cium, phosphorus, and alkaline phosphatase levels be-
tween the groups. Serum aluminum levels were
significantly higher among the peritoneal dialysis patients
than among the hemodialysis patients (17.0  11.1 mg/L
vs. 13.1  6.7 mg/L, p Z 0.039).
The majority of patients underwent total para-
thyroidectomy and autotransplantation (Table 2). Overall,
89 (26%) hemodialysis patients underwent concurrent thy-
roidectomy for benign goiter (n Z 73), thyroiditis (n Z 3),
or papillary thyroid cancer (n Z 13). Six peritoneal dialysis
patients underwent concurrent thyroidectomy for benign
goiter. The average postoperative hospital stay was
5.0  3.6 days (range, 2e42 days). Both groups showed
similar postoperative recovery. Persistent disease was
observed in 46 (12%) patients. The dialysis modality did not
influence the prevalence of persistent disease.
In both groups, serum calcium, phosphorus, alkaline
phosphatase, and intact PTH levels decreased significantly
Table 1 Characteristics of 386 patients with renal hyperparathyroidism.
Hemodialysis (n Z 346) Peritoneal dialysis (n Z 40) p
Age (y) 55  11 50  10 0.002
Female (n) 212 (61) 22 (55) 0.442
Duration of dialysis (y) 9.9  4.9 6.3  3.9 <0.001a
Body weight (kg) 60  13 63  13 0.152b
Body mass index (kg/m2) 23.5  4.0 24.3  3.8 0.326b
Preop bone mineral density (T score) 1.6  1.4 1.1  1.5 0.087
Preop bone mineral density (Z score) 0.6  1.1 0.4  1.3 0.598
Preop hemoglobin (g/dL) 11.0  1.7 10.2  1.9 0.006b
Preop albumin (g/dL) 4.2  0.5 4.0  0.4 0.040
Preop corrected calcium (mg/dL) 10.6  0.9 10.7  0.9 0.584
Preop phosphorus (mg/dL) 6.0  1.3 6.4  1.6 0.118a
Calciumephosphorus product (mg2/dL2) 64.1  14.5 68.0  13.6 0.120
Preop alkaline phosphatase (IU/L) 304  288 275  329 0.196b
Preop parathyroid hormone (pg/mL) 1384  430 1238  313 0.039
Data are presented as n (%) or mean  standard deviation.
Preop Z preoperative.
a Analysis after square root transformation.
b Analysis after logarithmic transformation.
Table 2 Perioperative features in patients undergoing parathyroidectomy for renal hyperparathyroidism.
Hemodialysis (n Z 346) Peritoneal dialysis (n Z 40) p
Subtotal parathyroidectomy 119 (34) 11 (28) 0.382
Concurrent thyroidectomy 89 (26) 6 (15) 0.175
Removed parathyroid weight (mg) 3152  2446 2740  1689 0.292a
Length of postoperative stay (d) 5.0  3.7 4.3  2.6 0.088a
Persistent disease 42 (12) 4 (10) > 0.99
Data are presented as n (%) or mean  standard deviation.
a Analysis after logarithmic transformation.
Dialysis modalities and parathyroidectomy 153after 1 month of parathyroidectomy. During follow-up,
intact PTH (Figure 1) and alkaline phosphatase (Figure 2)
levels were comparable between the groups. Serum cal-
ciumephosphorus product levels were comparable be-
tween the groups prior to surgery and were higher among
the peritoneal dialysis patients at 1 month postoperativelyFigure 1 Mean intact parathyroid hormone (PTH) levels after
parathyroidectomy in patients on hemodialysis (HD) or peri-
toneal dialysis (PD) over time. Error bars indicate standard
deviations. *p < 0.05.(p Z 0.001; Figure 3). The difference did not reach sta-
tistical significance at 6 (p Z 0.082) and 12 months post-
operatively (p Z 0.342). During a mean follow-up of 3.7
years, 10 (3%) patients developed recurrent hyperparathy-
roidism. All recurrences occurred beyond 1 year after
surgery.Figure 2 Mean total alkaline phosphatase levels after para-
thyroidectomy in patients on hemodialysis (HD) or peritoneal
dialysis (PD) over time. Error bars indicate standard deviations.
Figure 3 Mean serum calciumephosphorus product levels
after parathyroidectomy in patients on hemodialysis (HD) or
peritoneal dialysis (PD) over time. Error bars indicate standard
deviations. *p < 0.05.
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symptom items between the groups (Figure 4). After para-
thyroidectomy, peritoneal dialysis patients tended to have
more severe residual symptoms in three aspects compared
with hemodialysis patients (Figure 5): pain in the bones
(p Z 0.080), mood swings (p Z 0.053), and itchy skin
(p Z 0.094). The scores for difficulty getting out of a chair
or car were similar between the groups (p Z 0.337). For
hemodialysis patients, a decrease in symptom severity was
observed in almost all aspects including bone pain
(p Z 0.027), mood swings (p Z 0.047), itchy skin
(p < 0.001), and difficulty getting out of a chair or car
(p Z 0.006). By contrast, peritoneal dialysis patients did
not experience decreases in bone pain (p Z 0.224), mood
swings (p Z 0.546), and itchy skin (p Z 0.702).Figure 4 Preoperative Parathyroidectomy Assessment of Symptom
(HD) or peritoneal dialysis (PD). Error bars represent 95% confiden4. Discussion
We demonstrated that peritoneal dialysis patients who
underwent parathyroidectomy for renal hyperparathyroid-
ism had a shorter duration of dialysis and lower preopera-
tive intact PTH levels compared with hemodialysis patients.
Nonetheless, after surgery, the peritoneal dialysis patients
had higher calciumephosphorus product levels in the short
term and a tendency toward more severe residual symp-
toms compared with the hemodialysis patients.
As expected, we found that the surgical patients on
peritoneal dialysis were significantly younger. Peritoneal
dialysis is a feasible and safe option for elderly patients
with ESRD,16 but old age is associated with the adverse
outcomes of peritoneal dialysis-related peritonitis.17 This is
in keeping with the experience of other researchers. In
general, elderly patients and patients with peripheral
vascular disease, cerebrovascular disease, malignancy, and
multiple comorbidities are less likely to receive peritoneal
dialysis.18 In Taiwan, younger patients who received peri-
toneal dialysis had more favorable survival than patients
who received hemodialysis.19 By contrast, among ESRD
patients with cardiovascular disease or diabetes mellitus,
peritoneal dialysis may be associated with poor survival.20
In the present study, the peritoneal dialysis patients
underwent parathyroidectomy after a shorter duration of
dialysis and at a lower PTH level. Although this finding may
suggest treatment and referral bias, higher serum
aluminum levels in these patients suggest that more peri-
toneal dialysis patients fail to be adequately treated with
calcium-based phosphate binders. Data from the National
Health Insurance Research Database showed that perito-
neal dialysis patients had a higher incidence rate of para-
thyroidectomy (hazard ratio, 1.657) compared with
hemodialysis patients.21 The PTH level is not the only factor
in surgical referral. For patients who changed froms (PAS) scores in hyperparathyroidism patients on hemodialysis
ce intervals.
Figure 5 Postoperative Parathyroidectomy Assessment of Symptoms (PAS) scores in hyperparathyroidism patients on hemodi-
alysis (HD) or peritoneal dialysis (PD). Error bars represent 95% confidence intervals.
Dialysis modalities and parathyroidectomy 155peritoneal dialysis to hemodialysis, a progressive rise in PTH
levels was observed.9 Higher PTH levels may be associated
with a higher risk of high-turnover bone disease. This may
partially explain why in Taiwan, hemodialysis patients had
a greater risk of hip fracture compared with peritoneal
dialysis patients.22 In our study, peritoneal dialysis patients
tended to have higher preoperative BMD than hemodialysis
patients, although the difference was not statistically
significant.
The perioperative course was similar for the two groups.
Parathyroidectomy was associated with higher short-term,
and lower long-term, mortality rates in ESRD patients.23
Short-term relative mortality risks did not differ appre-
ciably by dialysis modality. In both groups, intact PTH and
alkaline phosphatase levels decreased significantly after
surgery. Nevertheless, peritoneal dialysis patients had
higher postoperative calciumephosphorus product levels
and more severe residual symptoms compared with hemo-
dialysis patients. The observation may result from higher
serum aluminum levels. We clearly demonstrated that a
high serum aluminum level was associated with reduced
symptom improvement in patients undergoing para-
thyroidectomy.13 In this study, a marked difference was
observed in mood swings (p Z 0.053). A plausible expla-
nation is that peritoneal dialysis patients had lower levels
of 25-hydroxyvitamin D compared with hemodialysis pa-
tients.24 Research has suggested a role of vitamin D in mood
disorders. A limitation of our study is that serum levels of
25-hydroxyvitamin D were not determined in our patients.
The role of vitamin D deficiency requires further
investigation.
Pruritus was the most prominent symptom prior to
parathyroidectomy. Consistent with our previous finding,5
the mean score of itching significantly dropped from
51  30 to 31  29 (p < 0.001) in hemodialysis patients.
Nonetheless, the itching score of peritoneal dialysispatients did not change significantly (from 52  26 to
48 32, pZ 0.702). This phenomenon may be attributed to
higher calciumephosphorus product levels in the peritoneal
dialysis group than in the dialysis group, because histolog-
ical studies have shown more calcium depositions in skin
basal and spinous cells among patients with uremic pruri-
tus.25 A high calciumephosphorus product level increases
the risk of soft tissue and vascular calcification. ESRD pa-
tients have higher odds of having pruritus if the cal-
ciumephosphorus product level is high, and pruritus is
associated with poor outcomes and higher mortality risk.26
Another possibility is that peritoneal dialysis patients had
higher serum aluminum levels. As shown in our previous
study, a high serum aluminum level was associated with
reduced symptom alleviation.13
Data from the Taiwan National Health Insurance
Research Database suggest that ESRD patients with sec-
ondary hyperparathyroidism have a greater risk of devel-
oping thyroid cancer.27 For a substantial minority of these
patients, benign and malignant thyroid disease warranted
surgical treatment at the time of parathyroidectomy. In this
study, 95 (25%) patients had concurrent thyroid operations,
including 13 patients for papillary thyroid cancer. The
presence of thyroid neoplasms in our patients seems higher
than that in the general population. The underlying mech-
anisms were unclear, but a negative association between
PTH levels and some thyroid-disrupting agents (perchlo-
rate, nitrate, and thiocyanate) has been reported.28 At our
institute, surgeon-performed neck ultrasound is routinely
conducted prior to the surgery.29 A comprehensive thyroid
evaluation of patients referred for parathyroidectomy is
recommended.30
This study has several limitations. First, the study has a
retrospective and nonrandomized design. The number of
peritoneal dialysis patients was relatively small. Conse-
quently, large variations and nonsignificant differences may
156 K.-C. Ho et al.occur between pre- and postoperative PAS scores in this
patient group. A recent large series from Tainan showed
that 82 (9%) of 888 ESRD patients undergoing para-
thyroidectomy were on peritoneal dialysis.31 Differences
between dialysis modalities would be more pronounced in a
larger cohort of patients. In addition, our study was limited
by its relatively short follow-up period, which restricts the
ability to make meaningful conclusions regarding
recurrence.
In conclusion, our study showed that patients on hemo-
dialysis or peritoneal dialysis had similar decreases in intact
PTH and alkaline phosphatase levels after surgery. How-
ever, dialysis modalities may influence postoperative cal-
ciumephosphorus product levels and hyperparathyroidism-
associated symptoms.References
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